Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mehmet Altan

Showing results (131-140 of 154) with videos related to

Pageof 16
Sort By:
Research Square|January 29, 2025
Comparison of imaging-based single-cell resolution spatial transcriptomics profiling platforms using formalin-fixed, paraffin-embedded tumor samplesNejla Ozirmak Lermi, Max Molina Ayala, Sharia Hernandez Ruiz, et al.
Biorxiv : the Preprint Server for Biology|January 7, 2025
Comparison of imaging-based single-cell resolution spatial transcriptomics profiling platforms using formalin-fixed, paraffin-embedded tumor samplesNejla Ozirmak Lermi, Max Molina Ayala, Sharia Hernandez, et al.
Cancer Cell|July 12, 2022
Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivityYasir Y Elamin, Jacqulyne P Robichaux, Brett W Carter, et al.
Frontiers in Medicine|June 18, 2025
Bronchoalveolar lavage cell percentages as diagnostic markers of immune checkpoint inhibitor pneumonitisMahnoor Mir, Felipe Soto, Pedro Antonio Amezcua Gomez, et al.
The Oncologist|May 8, 2023
Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center ExperienceMehmet Altan, Felipe Soto, Linda L Zhong, et al.
Journal for Immunotherapy of Cancer|July 4, 2023
Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trialMehmet Altan, Yan Wang, Juhee Song, et al.
Frontiers in Medicine|July 11, 2025
Correction: Bronchoalveolar lavage cell percentages as diagnostic markers of immune checkpoint inhibitor pneumonitisMahnoor Mir, Felipe Soto, Pedro Antonio Amezcua Gomez, et al.
JTO Clinical and Research Reports|October 14, 2024
Three-Year Overall Survival Outcomes and Correlative Analyses in Patients With NSCLC and High (50%-89%) Versus Very High (≥90%) Programmed Death-Ligand 1 Expression Treated With First-Line Pembrolizumab or CemiplimabBiagio Ricciuti, Arielle Elkrief, Jessica Lin, et al.
Cancer Letters|June 18, 2026
Deep Learning of CT Imaging Predicts PD-L1 Expression and Immunotherapy Response in Metastatic NSCLC: A Multi-Center StudyAmgad Muneer, Eman Showkatian, Maliazurina B Saad, et al.
Lancet (London, England)|July 21, 2023
Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trialJoe Y Chang, Steven H Lin, Wenli Dong, et al.
Pageof 16

Showing results (131-140 of 154) with videos related to

Sort By:
Pageof 16
Research Square|January 29, 2025
Comparison of imaging-based single-cell resolution spatial transcriptomics profiling platforms using formalin-fixed, paraffin-embedded tumor samplesNejla Ozirmak Lermi, Max Molina Ayala, Sharia Hernandez Ruiz, et al.
Biorxiv : the Preprint Server for Biology|January 7, 2025
Comparison of imaging-based single-cell resolution spatial transcriptomics profiling platforms using formalin-fixed, paraffin-embedded tumor samplesNejla Ozirmak Lermi, Max Molina Ayala, Sharia Hernandez, et al.
Cancer Cell|July 12, 2022
Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivityYasir Y Elamin, Jacqulyne P Robichaux, Brett W Carter, et al.
Frontiers in Medicine|June 18, 2025
Bronchoalveolar lavage cell percentages as diagnostic markers of immune checkpoint inhibitor pneumonitisMahnoor Mir, Felipe Soto, Pedro Antonio Amezcua Gomez, et al.
The Oncologist|May 8, 2023
Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center ExperienceMehmet Altan, Felipe Soto, Linda L Zhong, et al.
Journal for Immunotherapy of Cancer|July 4, 2023
Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trialMehmet Altan, Yan Wang, Juhee Song, et al.
Frontiers in Medicine|July 11, 2025
Correction: Bronchoalveolar lavage cell percentages as diagnostic markers of immune checkpoint inhibitor pneumonitisMahnoor Mir, Felipe Soto, Pedro Antonio Amezcua Gomez, et al.
JTO Clinical and Research Reports|October 14, 2024
Three-Year Overall Survival Outcomes and Correlative Analyses in Patients With NSCLC and High (50%-89%) Versus Very High (≥90%) Programmed Death-Ligand 1 Expression Treated With First-Line Pembrolizumab or CemiplimabBiagio Ricciuti, Arielle Elkrief, Jessica Lin, et al.
Cancer Letters|June 18, 2026
Deep Learning of CT Imaging Predicts PD-L1 Expression and Immunotherapy Response in Metastatic NSCLC: A Multi-Center StudyAmgad Muneer, Eman Showkatian, Maliazurina B Saad, et al.
Lancet (London, England)|July 21, 2023
Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trialJoe Y Chang, Steven H Lin, Wenli Dong, et al.
Pageof 16